Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional Study (NIS) to Examine the Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

NCT06494540 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06494540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06494540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional Study (NIS) to Examine the Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 28, 2024
Completion date
December 31, 2029
Enrollment
600 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous metastatic non-small-cell lung carcinoma